Grifols (GRFS) Retained Earnings (2009 - 2025)
Grifols' (GRFS) quarterly Retained Earnings came in at -$132.7 million in Q4 2025, down 116.0% YoY from $829.2 million in Q4 2024, and down 116.0% on a QoQ basis from $829.2 million in Q4 2024.
Grifols (GRFS) Retained Earnings (2009 - 2025) Analysis & Trends
Grifols (GRFS) has 17 years of Retained Earnings data on file, last reported at -$132.7 million in Q4 2025.
- Quarterly Retained Earnings fell 116.0% year-over-year to -$132.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$132.7 million (down 116.0% YoY) and the FY2025 annual result came in at -$132.7 million, down 116.0% from the prior year.
- Retained Earnings slipped to -$132.7 million in Q4 2025, from $829.2 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $4.7 billion in Q4 2021 to a low of -$132.7 million in Q4 2025.
- A 5-year average of $2.1 billion and a median of $829.2 million in 2024 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2023 — Retained Earnings soared 485.98% — and 2025, when it sank 116.0%.
- Tracing GRFS's Retained Earnings over 5 years: stood at $4.7 billion in 2021, then slumped by 84.31% to $742.0 million in 2022, then surged by 485.98% to $4.3 billion in 2023, then plunged by 80.93% to $829.2 million in 2024, then slumped by 116.0% to -$132.7 million in 2025.
- The last three Retained Earnings figures came in at -$132.7 million (Q4 2025), $829.2 million (Q4 2024), and $4.3 billion (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 171.67 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -17.33 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 63.27 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 12.59 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -22.28 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 9.53 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 112.09 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 15.38 Bn |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -132.70 Mn |
| Dec 31, 2024 | 829.23 Mn |
| Dec 31, 2023 | 4.35 Bn |
| Dec 31, 2022 | 741.98 Mn |
| Dec 31, 2021 | 4.73 Bn |
| Sep 30, 2020 | 4.71 Bn |
| Mar 31, 2020 | 4.44 Bn |
| Dec 31, 2019 | 3.33 Bn |
| Sep 30, 2019 | 3.10 Bn |
| Dec 31, 2018 | -28.12 Mn |
| Sep 30, 2018 | 2.85 Bn |
| Jun 30, 2018 | 2.93 Bn |
| Mar 31, 2018 | 3.73 Bn |
| Dec 31, 2017 | 2.39 Bn |
| Jun 30, 2017 | 2.23 Bn |
| Dec 31, 2016 | 1.83 Bn |
| Sep 30, 2016 | 1.89 Bn |
| Jun 30, 2016 | 1.92 Bn |
| Dec 31, 2015 | 1.50 Bn |
| Sep 30, 2015 | 1.53 Bn |